Company intelligence / Profile preview

Astria Therapeutics

Boston, Massachusetts, United Statesastriatx.com ↗

Ownership: Public · ATXS
Employees: ~78
Development stage: Phase 2

Overview

Astria Therapeutics has initiated the Phase 3 ALPHA-ORBIT trial of navenibart (STAR-0215) for HAE with top-line results expected in early 2027. They also announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 for HAE. Additionally, they initiated a Phase 1a trial of STAR-0310 for atopic dermatitis with early proof-of-concept results anticipated in Q3 2025.

Therapeutic areas: ImmunologyDermatology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

11 assets

navenibart

10 more assets in the full pipeline.

Request access →

Financials

Market cap: $718.1M
Total revenue: $706K
Enterprise value: $494.9M

Beyond the preview

Go deeper on Astria Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astria Therapeutics.

Explore the full profile